Besifovir dipivoxil

DB05020InvestigationalSmall molecule

Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of... Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.

Mechanism: Besifovir dipivoxil is an inhibitor of the HBV polymerase. It is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.
Curator reviewed
Primary indication: Investigated for use/treatment in hepatitis (viral, B).Curator reviewed
Formula / weight: C₂₂H₃₄N₅O₈P · 527.515 g/mol (avg)
Code names: AN-380 · ANA380 · LB-80380

Resolves to

Compound

UNIIS9I9P4J8IUCAS441785-26-8ChEMBLCHEMBL1652128

Structure

InChIKeyJLKJXDOWBVVABZ-UHFFFAOYSA-NSMILESCC(C)(C)C(=O)OCOP(=O)(COC1(CN2C=NC3=CN=C(N)N=C23)CC1)OCOC(=O)C(C)(C)C

Targets

O11885P

What you can answer from here — as of June 12, 2020

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Besifovir dipivoxil, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account